Search results
Julian Assange ends stalemate with US, exchanging guilty plea for his freedom
CNN.com· 6 days agoWikiLeaks founder Julian Assange has landed back home in Australia, a free man for the first time in...
Napoleon’s Loot: When the World Decided Stolen Art Should Go Back
The New York Times via Yahoo News UK· 3 days agoAMSTERDAM — In September 1815, Karl von Müffling, the Prussian governor of Paris, presented himself...
“I miss him every minute, of course”: Avicii’s father talks about his grief
MusicRadar via Yahoo News UK· 4 days agoThe footage was first screened at the Avicii Experience, the tribute museum to the DJ in his...
Julian Assange is back in Australia a free man. Here’s what we know about his US plea deal
CNN via Yahoo News UK· 6 days agoWikiLeaks founder Julian Assange pled guilty to a single espionage charge in front on a US judge...
Intrum sells part of portfolio to Cerberus with lower proceeds than planned
Reuters· 20 hours ago, opens new tab said on Monday it had completed the sale of a large portion of its investment portfolio to Cerberus with-lower-than-expected net proceeds of 7.2 billion crowns ($682.17 million ...
Scientists say freak event killed woolly mammoths
Daily Mail· 1 day agoWoolly mammoths traversed the Ice Age tundras of North America, Europe and Asia as far back as 300...
Modi to Visit Russia for First Time Since Invasion of Ukraine
Bloomberg via Yahoo News UK· 7 days ago(Bloomberg) -- Sign up for the India Edition newsletter by Menaka Doshi – an insider's guide to the...
Xponential Fitness (XPOF) to Expand BFT Line-up in Scandinavia
Zacks via Yahoo Finance UK· 5 days agoThe deal marks the company’s first brand entry in the Scandinavian region. Per the agreement, Tage...
Elton John officially confirms he will never tour again — here’s why
NY Post· 3 days agoThe EGOT winner’s final world tour, “Farewell Yellow Brick Road,” began in 2018 in North America and...
Almirall’s Ilumetri® (tildrakizumab) restores and maintains wellbeing of patients with...
PharmiWeb· 4 days ago• Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab)I in ...